NCT02639260View on ClinicalTrials.gov

A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 7, 2016

Primary Completion Date

June 5, 2018

Study Completion Date

June 5, 2018

Conditions

Kidney Disease

Interventions

DRUG

N-acetyl D-mannosamine

dose escalation

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT02639260 - A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases | Biotech Hunter | Biotech Hunter